Donaldson Company, Inc. (NYSE:DCI) Q2 2023 Earnings Call Transcript

Donaldson Company, Inc. (NYSE:DCI) Q2 2023 Earnings Call Transcript March 1, 2023

Company Representatives: Tod Carpenter – Chairman, Chief Executive Officer, President Scott Robinson – Chief Financial Officer Sarika Dhadwal – Senior Director of Investor Relations

Operator: Good morning. My name is Emma, and I will be your conference operator today. At this time, I would like to welcome everyone to the Donaldson Company, Second Quarter 2023 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. . Thank you. Sarika Dhadwal, Senior Director of Investor Relations, you may begin your conference.

Sarika Dhadwal: Good morning. Thank you for joining Donaldson’s second quarter fiscal 2023 earnings conference call. With me today are Tod Carpenter, Chairman, CEO and President; and Scott Robinson, Chief Financial Officer. This morning Tod and Scott will provide a summary of our second quarter performance and an update on our outlook for fiscal 2023. As a reminder, we are now reporting our results under three segments: Mobile Solutions, Industrial Solutions and Life Sciences. On January 25 we provided an 8-K showing select historical financial performance under this new segment structure. This 8-K as well as our regular supplemental quarterly earnings presentation can be found on our Investor Relations website at ir.Donaldson.com.

During today’s call, we will discuss non-GAAP or adjusted results. For the second quarter of fiscal 2023, non-GAAP results exclude $9.3 million of non-recurring, pretax, restructuring and other changes, largely related to our previously announced organizational redesign, as well as costs associated with the exiting of the lower margin customer program. A reconciliation of GAAP to non-GAAP metrics is provided within the schedules attached to this morning’s press release. Additionally, please keep in mind that any forward-looking statements made during the call are subject to risks and uncertainties, which are described in our press release and SEC filings. With that, I’ll now turn the call over to Tod Carpenter. Please go ahead.

Tod Carpenter: Thanks Sarika. Good morning, everyone. I am pleased to report Donaldson company’s strong second quarter earnings results. Significant gross margin expansion driven by favorable pricing and the continued stabilization of input costs resulted in an operating margin above 15%. For the second quarter in a row, we achieved an operating margin at a six year quarterly high. This quarter, Donaldson operated under our new organization structure designed to better serve our end market customers, and I am confident and excited about the direction in which we are heading. We are now positioned to manage the organization more efficiently with our three segments supported by our operational capabilities, strong balance sheet and targeted strategic investments.

For example, we now have a more straightforward task to sharpen our focus on the newly created Life Sciences segment and pursue accelerated growth. In February, we added to our Life Sciences portfolio by acquiring Isolere Bio, an early stage biotechnology company for approximately $63 million. Based in Durham, North Carolina, Isolere develops novel and proprietary reagents and accompanying filtration processes used for the purification and streamlined manufacturing of biopharmaceuticals. This technology is designed to substantially improve product quality and purity with faster timelines compared to competing solutions, enabling accelerated and more affordable delivery of life changing therapies to patients globally. One of the most compelling components of this acquisition is the ability for Donaldson through our portfolio of offerings, including those from Solaris and Purilogics to provide customers a full suite of products which can be integrated into the downstream biomanufacturing process.

This highlights the string of pearls approach we have taken to grow the Life Sciences segment. As we execute our go-to-market strategy for these combined solutions, we are building a biopharma focused sales force to capitalize on the opportunities ahead. I’ll talk more about Donaldson’s path forward a little later, but first we’ll cover second quarter highlights. Sales were up 3% year-over-year, driven by pricing of 10% and offset by a currency translation headwind of approximately 4%. Volume decreased slightly this quarter, primarily due to the softness in our aftermarket and Disk Drive business. Adjusted EPS of $0.75 was up 32% versus the second quarter of fiscal 2022. We continue to see topline and margin benefits from our pricing actions, and while input costs undoubtedly remain elevated, many are slowly coming off peak levels.

Overall end market demand remains solid, and with improvements in global supply chain conditions, this quarter we improved our fill rates, reduced our backlog and are returning to more normalized, on-time delivery rates. Each quarter, while we focus on near term execution, we also thoughtfully plant seeds for future profitable growth through our investments, including those in M&A and R&D. I am pleased with the pieces of the Life Sciences business we have put together and with the integration progress we are making with Solaris and Purilogics. However, we still have a long way to go in building this business and are actively pursuing other opportunities, both organic and inorganic in this space. We are also investing in other higher margin areas such as services.

For example, within the Industrial Solutions segment this quarter, we added on to our service offering through the rollout of managed filtration services. Through this offering, Donaldson provides complete and customizable service plans for our industrial filtration equipment. These range from condition based maintenance plans that leverage our proprietary IQ technology to traditional time based maintenance and repair services needed to keep critical, industrial equipment and compliance and online. From a capital expenditure standpoint, our investments are also heavily weighted towards growth with capacity expansion, particularly in North America accounting for the largest portion. To summarize, we are encouraged by the ongoing improvements we are seeing from an operational standpoint and excited about the groundwork we are laying for Donaldson’s future.

Now, we’ll provide some detail on second quarter sales. Total company sales were $828 million, up 3% compared with 2022. In Mobile Solutions, total sales were $522 million, up about 2%. Pricing added 12% and FX was an approximate 4% headwind. Sales in Off-Road of $106 million were up 16%. Elevated equipment production levels and strength in our Exhaust and Emissions business in Europe drove sales. On-Road sales were $35 million, a 4% increase from prior year, benefiting from strong, medium and heavy duty truck production. Excluding currency, sales in both of our first hit businesses were up in all regions. Mobile Solutions aftermarket sales were $382 million, down approximately 2% versus prior year. Excluding currency, sales were up roughly 2% as pricing was partially offset by customer inventory reductions in both the OE and independent channels.

Not surprising, the improvement in global supply chain conditions has a lot of return to more normalized channel inventory levels. Lastly, for Mobile Solutions, I would be remiss if I did not talk about China. Broad based market pressures, negative impacts from the end of zero COVID and the timing of Chinese New Year, which fell in January this year versus February last year, all weighed heavily on second quarter China results. Sales declined 30% year-over-year and 25% in constant currency. The environment in China has certainly been challenging. However, given the share market size and our differentiated technology and high quality offerings, we continue to view China as a long term growth opportunity. Now, I’ll turn to the Industrial Solution segment.

Industrial sales increased 13% to $246 million. Pricing added 6% and FX was a 4% headwind. Industrial Filtration Solutions or IFS drew 11% to $212 million, driven by dust collection new equipment and replacement part sales and power generation project timing. Aerospace and Defense sales, which now fall within the Industrial Segment continue to benefit from the recovering commercial aerospace industry and were up 28% versus prior year. Now, on the Life Sciences segment. Life Sciences sales were $59 million, down 16% as continued Disk Drive market weakness weighed heavily on segment sales. Excluding Disk Drive, Life Sciences sales would have increased approximately 7%. We are seeing encouraging sales trends in food and beverage and bioprocessing equipment.

These remain key strategic growth areas for Donaldson, and we look forward to providing updates on our progress in the future. Overall, our first half fiscal 2023 results were robust, and I’m confident we will continue to deliver on our financial and strategic commitment for the balance of the year. As such, we are tightening our full year EPS guidance range to the high end of our previous range to reflect our conviction. We are proud of our performance and remain on pace to achieve another year of record sales, record earnings and multi decade high operating margin. Now, I’ll turn it over to Scott for more details on the financials and a more detailed update on our outlook for fiscal €˜23. Scott.

Scott Robinson : Thanks, Tod. Good morning, everyone. Our results this quarter were solid. In our view, this is a reflection of how well our employees around the globe maintain their focus on delivering to our customers, while working through the completion of the organizational redesign. This redesign was certainly a heavy lift for the company, but I truly believe we are now better positioned than ever for future profitable growth, and I thank our teams for the contributions in this regard. I will provide color on our outlook for the balance of the year in a few minutes, but first I will give more details on second quarter results. To summarize the quarter, sales grew 3%. Operating income was up 31%, and adjusted EPS of $0.75 increased 32% year-over-year.

Gross margin of 34.5% improved 340 basis points versus 2022. It was worth noting that gross margin in the second quarter of fiscal 2022 was 31.1%, a very low level for the company as the timing of our pricing actions lag historic levels of inflation. Pricing now of course plays a significant role in our year-over-year improvement as is the stabilization of input costs. From a sequential standpoint, gross margin did not follow our typical seasonal pattern, and increased 60 basis points, due mainly to inventory valuation. As a result, for the third quarter, we are forecasting gross margin to step down sequentially, however we still anticipate a year-over-year improvement. Operating expenses as a percent of sales were 19.3%, slightly above 19.2% a year ago.

The slight increase was due in large part to the comparison of prior year as we were still in the early days of the pandemic related recovery. Operating margin was 15.2%, up 330 basis point versus prior year resulting from gross margin expansion. Operating margin was up 20 basis sequentially. Again, this does not following our typical seasonal pattern. Further given our third quarter gross margin expectations, we also anticipate a corresponding step down in sequential operating margin in the third quarter, but a year-over-year improvement. Now, I’ll touch on segment profitability. Mobile Solution’s pretax profit margin was 15%, up 360 basis points a year-over-year, and the Industrial Solutions pretax margin was 18.8%, up 640 basis points from the prior year.

Gross margin expansion, along with operating expense leverage were the drivers in both segments. On the Life Science side, pretax profit margin was 10.6% down notably from 23.7% a year ago. The decline in Disk Drive sales was the largest driver, combined with increased operating expenses as we continue to invest heavily in this segment. Excluding acquisitions, pretax profit margin would have been 16.4%. Turning to a few balance sheet and cash flow statement highlights. Second quarter capital expenditures were roughly $30 million, mainly driven by capacity expansion investments in North America. Cash conversion in the quarter was 78% versus about 30% in 2022. This improvement reflects a return to more normal levels of conversion, following the negative inventory related to working capital impacts in the prior year.

In terms of capital deployment, we returned $98 million to shareholders with $28 million in the form of dividends and $70 million in share repurchases. Our balance sheet is in great shape as we entered the quarter with a net debt to EBITDA ratio of 0.8x. Now moving to our updated fiscal €˜23 outlook. For sales, given the new segmentation, I won’t go through the exercise of bridging back to our previous guidance for each segment. That said, at a high level our outlook for total company sales and legacy engine and industrial segments has not materially changed. We expect fiscal 2023 sales to increase between 2% and 6% above our previous guidance of between 1% and 5%. This includes a negative impact from currency translation of about 4%, which is an improvement of 100 basis points from what we expected last quarter.

Pricing should contribute about 6% to sales. As a reminder, second half year-over-year sales growth will be lower than first half as incremental pricing benefits begin to fade. For Mobile Solutions, we are forecasting a revenue increase of between 1% and 5%. Given recent trends, the composition of mobile sales is now expected to be different from our initial projections as stronger than expected end market demand for our first fit products, mainly Off-Road is forecasted to offset weaker than expected aftermarket sales. On-Road and Off-Road sales are expected to be up mid-single digits and high single digits, respectively. Aftermarket sales are projected to be up low single digits. As Tod mentioned, customer inventory reductions in response to improved supply chain conditions are impacting sales in both aftermarket channels.

In the Industrial Solutions segment, we expect sales growth of between 8% and 12%, driven by continued strength in IFS, Dust Collection new and replacement parts in particular, and Aerospace and Defense. IFS are forecasted to increase high single digits, and Aerospace and Defense sales are projected to grow low double digits. For the Life Sciences segment, we are forecasting a sales decline of between 5% and 9%. Disk Drive sales have been negatively impacting results. However, we do anticipate a stabilization in sales in the second half of the year. We also expect continued strength in food and beverage and bioprocessing equipment or Solaris sales. In terms of operating margin, we are narrowing our guidance to between 14.6% and 15.0%. The midpoint of its range reflects a 130 basis point increase from prior year, primarily driven by gross margin improvement.

From an operating expense perspective, while we continue to exercise discipline, particularly given the uncertain macro environment, we are committed to building for the future through our reinvestments back into the business. With respect to EPS, we are now expecting results within a range of $2.99 and $3.07 towards the higher end of our previous range of $2.91 and $3.07. The midpoint of our new EPS guidance range represents an approximately 13% increase from a record fiscal 2022. Now, onto our balance sheet and cash flow outlook. Cash conversion is forecast in the range of 110% and 120% higher than our historical averages and in line with our previous guidance. The strong cash conversion from this year is expected to be driven by benefits from improved inventory efficiency as we continue to refine our processes, and as supply chain conditions normalize.

Our capital expenditures forecast heavily weighted towards growth initiatives is between $115 million and $130 million. This includes investments in capacity expansion, along with tooling and equipment for new products and technologies. Our remaining capital deployment priorities include additional investments in Donaldson’s inorganic growth, specifically in Life Sciences as evidenced by the Isolere acquisition and services, as well as our online commitment to dividend and share repurchases. Now, I’ll turn the call back to Tod. Tod.

Tod Carpenter : Thanks, Scott. I would like to express my deep gratitude to our dedicated Donaldson team. Their commitment to our organization and to our customers and their professionalism through the redesign has been truly wonderful. I’m excited about our path forward. Looking ahead, Donaldson’s goal is to remain the leader in technology led filtration and to support our people, our customers and our communities in advancing filtration for a cleaner world. First, on supporting our people. Building on our strong technological foundation, our engineers for example are hard at work every day growing our innovation engine. They are supported by our commitment to R&D and are developing products and services in our higher margin higher growth areas.

Second, supporting our customers. As a corporation, we have our own sustainability goals. However €“ and not to be understated, our products and solutions are inherently well suited to support our customers as they work to achieve their sustainability goals. And last but not least, supporting our communities. Being able to leverage our filtration and separation technologies into different verticals is one of the key competitive advantages of Donaldson. Through our expansion into Life Sciences, we have now begun to play an increasingly important role in supporting the improvement of global human health. In closing, we are incredibly optimistic as we look out over the long term. We look forward to providing additional color on Donaldson’s long term strategy, growth drivers and key initiatives, including those related to innovation and ESG at our upcoming Investors Day on April 4.

At that time we will also share our longer term financial objectives. Now, I’ll turn the call back to the operator to open the line for questions.

See also 10 Best Stocks to Buy and Hold for a Lifetime and 12 Best AI Stocks for 2023.

Q&A Session

Operator: Thank you. Your first question today comes from the line of Bryan Blair with Oppenheimer. Your line is now open.

Bryan Blair : Thank you. Good morning, everyone.

A – Tod Carpenter: Good morning.

Bryan Blair : Another very solid quarter, and I guess as we think about the back half, you’re I suppose somewhat of a victim of your own success given the stacked comps that you face. I apologize if I missed this in the bread crumbs provided in the outlook, but how should we think about Q3, Q4 cadence, you know top line and EPS as a €“ I guess at a high level, you know think of moderate growth in Q3, moderate decline in Q4, further more nuance to that.

A – Scott Robinson: Yes, so €“ Hi Bryan! This is Scott. Nice to talk to you. So we held our guidance for the year you know relatively flat, excluding FX which had improved for us by 100 basis points. So that was the largest change in the guidance that impacted you know our back half of the year. It is kind of interesting this year when we look at our revenue cadence. You know if you look at last year, you know we had a strong ramp throughout the year, starting with first quarter revenues of $761 million and ending the year at $890 million, so a strong and steady ramp throughout the year to get to $3.3 billion. This year you know we said we were going to return to more normal level seasonality and for Donaldson that’s traditionally been 49/51 or 48/52 and so our revenues are much flatter throughout the year, with a little bit of a tilt to the second half, just like we normally have historically to get to the $3.4 billion.

So you know we’re not going to give quarterly guidance, but our revenues you know in the back half of the year are relatively consistent. And you get the big percentage swings when you compare year-over-year, because of the strong ramp from the prior year. In terms of profit we talked a little bit about gross margins and operating margins and we’re a little bit unseasonal I would say this year, and to the future gross margin questions that we’re going to get, you know there’s really a lot going on in terms of FX, in terms of inflation, in terms of accounting variances and you have some stock moving from quarter-to-quarter to make sure you’re matching your variances with the inventory. And when you look at our margins, you really have to look at the first, second and third quarters and put them together, because you’ve got some stuff moving around and you got a lot of volatility in the income statement, and we would hope as we move to the future, you know that inflation stabilizes, currency stabilizes and we get some more accounting stabilization in our income statement, and that will make our gross margins a little more easy to understand.

But if you put the quarters together, you can see strong gross margin improvement and we’re just trying to manage you know our third quarter versus second quarter, and that’s why we added the comments in the script. So hopefully, that’s a few more bread comes that helped with your puzzle, and hopefully that helps with your question.

Bryan Blair : Yeah, absolutely! I appreciate the detail. In terms of Life Science Q2 profit declines Scott, you said that the impact was weighted to the decline in Disk Drive business, which is understandable. It’s a meaningful percentage of revenue, and its high margin. Could you specifically parse out you know what the impact was of Disk Drive declines versus growth investment, either in terms of the EBIT dollar decline or margin contraction?

Tod Carpenter: We’ve not €“ Bryan, this is Scott. So we’ve not really disclosed that level of detail. We will give you more forward looking at the investment day, at our Investor Day relative to our strategy. On a forward look on Life Sciences, relative to what we’re experiencing right now with Disk Drive, the decline has been very acute. It’s down between 40% and 50%, and we would look for it to have tough comps for a few more quarters, I think about three, and then we’ll have lapped this, and then we’ll be able to start crawling forward. We do believe that it has bottomed. In fact, it looks like it has bottomed in December, but it is also going to bounce at these very low levels for the foreseeable future.

Bryan Blair : Okay, understood. And you mentioned Investor Day, looking forward to that next month and I imagine we’ll hear quite a bit more on this front at Investor Day. It will be great to hear a little more color on how Isolere furthers thestring of pearls M&A build out of your Life Sciences platform and how Solaris, Purilogics, Isolere piece together in terms of the platform capabilities and what that signals in terms of your path forward.

A – Tod Carpenter: Absolutely! We’ll give you that complete story on April 4.

Bryan Blair : Okay, I’ll leave it there. Thanks guys.

Operator: Your next question comes from the line of Laurence Alexander with Jefferies. Your line is now open.

Dan Rizzo: Hey! It’s Dan Rizzo on for Laurence. Thank you guys for taking my question. You mentioned that China obviously was down given the COVID and the New Year, but as we’ve exited that, are you seeing order trends pick up or is it something you’re anticipating in the future.

Tod Carpenter: It’ll be more future looking. We’re still feeling the pressures across China. We you know delivered this quarter even with the tough China story still present, and so for us, the more positive outlook that China still lies ahead.